Systolic Heart Failure

08/01/2003 - "This study aimed to evaluate the effect of developing and implementing Clinical Practice Guidelines (CPGs) on the quality of care given to patients receiving ACE inhibitors for systolic heart failure. "
04/01/2015 - "Angiotensin-converting enzyme inhibitors (ACEIs) have been the cornerstone in systolic heart failure (HF) regimens over the past 25 years. "
03/01/2015 - "Use of different types of angiotensin converting enzyme inhibitors and mortality in systolic heart failure."
07/15/2013 - "Angiotensin-converting enzyme inhibitors improve outcomes in systolic heart failure (SHF). "
03/18/2010 - "Mortality and morbidity of non-systolic heart failure treated with angiotensin-converting enzyme inhibitors: a propensity-adjusted case-control study."

05/01/2012 - "In particular, the findings of the Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial (SHIFT) have put special emphasis on heart rate reduction with ivabradine for improvement in clinical outcomes. "
12/01/2015 - "Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial."
05/01/2015 - "Analysis of 24-h Holter recordings was a pre-specified substudy of SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial) for exploring the heart rhythm safety of ivabradine and to determine effects of ivabradine on 24-h, daytime, and night-time heart rate (HR) compared with resting office HR. The 24-h Holter monitoring was performed at baseline and 8 months after randomization to ivabradine (n = 298) or matching placebo (n = 304) titrated maximally to 7.5 mg b.i.d. "
02/01/2015 - "Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study."
09/01/2014 - "In the prospective, open-label multicenter INTENSIFY study, the effectiveness and tolerability of ivabradine as well as its impact on quality of life (QOL) in chronic systolic heart failure (CHF) patients were evaluated over a 4-month period. "

09/01/2015 - "Clinical systolic heart failure (HF) guidelines specify recommendations for ACE inhibitors (ACEI), angiotensin receptor blockers (ARB), and beta blockers according to doses used in clinical trials. "
12/01/2011 - "Age, gender, ejection fraction, systolic heart failure, angiotensin II receptor blockers use, hemoglobin levels, and handgrip strength were independent predictors of all-cause mortality. "
04/01/2012 - "Discharge prescription of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was associated with a significant modest reduction in all-cause mortality in older patients with systolic heart failure with chronic kidney disease, including those with more advanced chronic kidney disease."
04/01/2012 - "Of the 1665 patients (aged≥65 years) with systolic heart failure (ejection fraction<45%) and chronic kidney disease (estimated glomerular filtration rate<60 mL/min/1.73 m(2)), 1046 received angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. "
08/01/2008 - "Inhibition of renin-angiotensin system (RAS) activity using angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ARBs) is beneficial in patient populations with left ventricular dysfunction or systolic heart failure (HF) and other forms of heart disease. "

10/01/2015 - "The aim of this study was to evaluate the association of fibroblast growth factor (FGF)-23 with clinical and laboratory findings, the prognostic value of FGF-23, and the relationship between angiotensin-converting enzyme inhibitor (ACEi) therapy, FGF-23 levels, and outcomes in patients with chronic systolic heart failure (HF). "
10/01/2013 - "Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker. "
04/01/2012 - "The role of renin-angiotensin inhibition in older patients with systolic heart failure with chronic kidney disease remains unclear. "
04/01/2012 - "Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease."
05/01/2002 - "Combination treatment with a calcium channel blocker and an angiotensin blocker in a rat systolic heart failure model with hypertension."

08/01/2015 - "Aldosterone inhibitors have been shown to be beneficial for patients with systolic heart failure. "
02/01/2009 - "An aldosterone antagonist may be used in select patients with advanced systolic heart failure, carefully avoiding hyperkalemia."
03/01/2012 - "Evidence of interactions between aldosterone and the heart that occur independent of the renal effects of aldosterone, however, is not limited to the context of systolic heart failure and observations obtained in other disease states have led, together with findings of animal studies, to a better understanding of the potential benefits of aldosterone antagonists. "
03/01/2012 - "Indirect evidence of the untoward effects of aldosterone on the heart has been clearly established in clinical studies that have tested the effects of mineralocorticoid receptor antagonists in the treatment of systolic heart failure. "
04/03/2007 - "In patients with systolic heart failure, high levels of circulating aldosterone are associated with an adverse prognosis, and mineralocorticoid receptor blockade improves survival. "

04/01/2014 - "Recent studies have broadened the potential use of mineralocorticoid receptor antagonist (MRA) in patients with systolic heart failure after cardiovascular hospitalization. "
10/01/2014 - "Mineralocorticoid receptor antagonists (MRAs) have become mandated therapy in patients with reduced ejection fraction (systolic) heart failure (HF) across all symptom classes. "
12/01/2011 - "Although mineralocorticoid receptor (MR) antagonists are indicated in systolic heart failure, they are underprescribed in patients with appropriate indications for their prescription and often used in those in whom the evidence for probable benefit is scant. "
03/01/2014 - "Differential outcomes in patients with acute systolic heart failure (HF) complicating acute myocardial infarction (AMI) and the efficacy of mineralocorticoid receptor antagonists according to non-ST-segment and ST-segment elevation myocardial infarction (NSTEMI, STEMI) status has not been specifically investigated. "
01/01/2014 - "Mineralocorticoid receptor antagonists improve outcomes in patients with systolic heart failure but may induce worsening of renal function (WRF) and hyperkalemia (HK). "

01/01/2013 - "In two randomized cross-over-designed trials, 18 insulin-treated type 2 diabetic patients with (Ejection Fraction (EF) 36 ± 6%, n = 10) (trial 2) and without systolic heart failure (EF 60 ± 3%, n = 8) (trial 1) were subjected to hyper- and normoglycemia for 9-12 hours on two different occasions. "
11/29/2012 - "Impaired insulin sensitivity is common in patients with chronic systolic heart failure (CHF) and contributes to symptomatic status and impaired prognosis. "
01/01/2011 - "Patients with systolic heart failure had impaired insulin-stimulated endothelial function. "
09/30/2013 - "Does improved insulin sensitivity by irbesartan at the highest tolerated dose provide a benefit in non-diabetic patients with systolic heart failure already receiving standardized treatment?"
01/01/2011 - "Systolic heart failure and type 2 diabetes result in similar vascular insulin resistance and reduced muscular insulin-stimulated glucose uptake. "

09/30/2013 - "Does improved insulin sensitivity by irbesartan at the highest tolerated dose provide a benefit in non-diabetic patients with systolic heart failure already receiving standardized treatment?"
11/29/2012 - "Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study."

08/01/2008 - "Conversely, the angiotensin-converting enzyme D allele had no detectable impact on systolic heart failure phenotype. "
03/01/2008 - "The angiotensin-converting enzyme (ACE) inhibitor has a well defined place in the treatment of systolic heart failure (HF). "
01/01/2004 - "Racial response to angiotensin-converting enzyme therapy in systolic heart failure."
09/06/2011 - "Eight trials met criteria for review: 6 placebo-controlled trials involving 5,972 participants with chronic systolic heart failure and 2 angiotensin-converting enzyme inhibitor-comparator trials involving 977 participants not known to have heart failure. "
10/01/2013 - "Mixed-methods study of 295 veterans aged 50 years and older in 4 VA health care systems who had systolic heart failure and were not prescribed a β-blocker and/or an angiotensin converting enzyme inhibitor or angiotensin-receptor blocker. "

01/01/2015 - "This retrospective cohort study included patients with systolic heart failure (EF < 40%) receiving carvedilol. "
09/01/2011 - "Carvedilol has been the most effective beta-blocker in the treatment of the systolic heart failure. "
08/01/2008 - "To determine whether carvedilol can be safely up-titrated before hospital discharge, we studied 372 consecutive patients with systolic heart failure who were being treated with carvedilol. "
08/01/2008 - "Rapid carvedilol up-titration in hospitalized patients with systolic heart failure."
01/01/2008 - "Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol."

09/01/2009 - "Cardiac resynchronization therapy (CRT) is a novel treatment for systolic heart failure and in successful cases reverse remodeling occurs with reduction of left ventricular (LV) dimensions and volumes. "
09/01/2009 - "More recently, ICD therapy also has been shown to be effective for the primary prevention of SCD in patients with systolic heart failure, sometimes with the addition of cardiac resynchronization therapy. "
08/01/2008 - "Biventricular pacing has been shown to improve the overall clinical outcomes in patients with systolic heart failure and ventricular conduction delay on electrocardiogram. "
01/01/2012 - "Cardiac resynchronization therapy (CRT) is effective in reducing morbidity and mortality in systolic heart failure patients with cardiac dyssynchrony as demonstrated in studies with primarily Western populations. "
03/01/2012 - "Cardiac resynchronization therapy can be effective in systolic heart failure associated with LBBB developing after TAVI."

10/01/2008 - "Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice--results from a cluster-randomized controlled trial of implementation of a clinical practice guideline."
05/01/2006 - "Guideline recommendations for drug therapy are based in most cases on studies conducted in younger systolic heart failure patients. "
10/01/2010 - "Primary and tertiary literature, including subgroup analyses, published in English and relating to the use of pharmacotherapy in the treatment of systolic heart failure in the elderly was reviewed. "
10/01/2008 - "Clinical practice guidelines (CPG) reflect the evidence of effective pharmacotherapy of chronic (systolic) heart failure (CHF) which needs to be implemented. "
04/01/2008 - "There is robust evidence for effective pharmacotherapy of chronic (systolic) heart failure (CHF) which has led to the creation of guidelines, but many surveys evaluating CHF treatment show an under-utilisation of relevant drugs, while setting and patient population appear to be crucial for adequate appraisal of treatment patterns. "

09/01/2012 - "Guidelines recommend that patients with new-onset systolic heart failure (HF) receive a trial of medical therapy before an implantable cardiac defibrillator (ICD). "
03/04/2009 - "Cardiac resynchronization therapy by a biventricular pacemaker or defibrillator is recommended for treating selected patients with systolic heart failure who are in NYHA class III or IV despite optimal medical therapy, have a left ventricular ejection fraction of < or = 35%, and a QRS width of > or = 120 ms. Improvement in symptoms or ventricular remodelling is observed in 50-80% of patients. "
01/01/2012 - "We report the case of a 63-year-old male with chronic systolic heart failure referred for cardiac resynchronization therapy-defibrillator implant. "
02/01/2013 - "We report on 142 outpatients with systolic heart failure seen at our heart failure unit from 2007 to 2010 (ages 69.4 ± 8.9 years; ejection fraction [EF] 30.6 ± 6.1%; 43% with implanted defibrillators and/or resynchronization devices). "
03/15/2014 - "Digoxin provides symptomatic relief in patients with systolic heart failure, yet it has potential proarrhythmic mechanisms and has not been formally studied in patients with cardiac resynchronization therapy-defibrillators (CRT-Ds). "

11/01/2008 - "Safety and efficacy of bariatric surgery in morbidly obese patients with severe systolic heart failure."

08/01/2005 - "Safety and efficacy of repeated sauna bathing in patients with chronic systolic heart failure: a preliminary report."